<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Spironolactone: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Spironolactone: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Spironolactone: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9943" href="/d/html/9943.html" rel="external">see "Spironolactone: Drug information"</a> and <a class="drug drug_patient" data-topicid="11872" href="/d/html/11872.html" rel="external">see "Spironolactone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F222861"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Aldactone;</li>
<li>CaroSpir</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868284"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Aldactone;</li>
<li>JAMP-Spironolactone;</li>
<li>MINT-Spironolactone;</li>
<li>TEVA-Spironolactone</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1062344"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihypertensive Agent</span>;</li>
<li>
<span class="list-set-name">Diuretic, Potassium Sparing</span></li></ul></div>
<div class="block don drugH1Div" id="F53462596"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Although spironolactone is commercially available in a suspension, it is NOT therapeutically equivalent to the tablets; commercially available suspension results in 15% to 37% higher serum concentration compared to the tablet; pediatric dosing is based on experience with tablets and extemporaneously compounded suspension. Multiple concentrations of oral suspension exist; use extra precaution and prescribe in mg (not mL).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Bronchopulmonary dysplasia (BPD): </b>Limited data available; efficacy results variable. Although the benefits of diuretic therapy in the management of BPD are variable (eg, optimal duration of therapy, impact on pulmonary endpoints), diuretics continue to be used in clinical practice (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23478874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23478874'])">Ref</a></span>): Oral: 1.5 mg/kg/dose every 12 hours; used in combination with a thiazide diuretic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2677293','lexi-content-ref-2926575','lexi-content-ref-10693099','lexi-content-ref-21901679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2677293','lexi-content-ref-2926575','lexi-content-ref-10693099','lexi-content-ref-21901679'])">Ref</a></span>); used most often in preterm neonates at a PNA &gt;28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23478874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23478874'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Edema (diuresis):</b> Limited data available: Oral: 1 to 3 mg/kg/day in divided doses every 12 to 24 hours; used in combination with a thiazide diuretic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Eichenwald.2017','lexi-content-ref-Fanaroff.2013','lexi-content-ref-16898855']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Eichenwald.2017','lexi-content-ref-Fanaroff.2013','lexi-content-ref-16898855'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment in renal impairment: </b>Spironolactone is substantially excreted by the kidney; use with caution; monitor serum potassium closely; consider extended dosing intervals (eg, every 24 to 48 hours) for moderate renal impairment; avoid use in severe renal impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16898855']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16898855'])">Ref</a></span>)</p></div>
<div class="block dop drugH1Div" id="F222886"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Although spironolactone is commercially available in a suspension, it is NOT therapeutically equivalent to the tablets; commercially available suspension results in 15% to 37% higher serum concentration compared to the tablet; pediatric dosing is based on experience with tablets and extemporaneously compounded suspension. Multiple concentrations of oral suspension exist; use extra precaution and prescribe in mg (not mL).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4ddb56d1-0e77-423d-981b-3c407d3f8eea">Bronchopulmonary dysplasia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bronchopulmonary dysplasia (BPD): </b>Limited data available; efficacy results variable. Although the benefits of diuretic therapy in the management of BPD are variable (eg, optimal duration of therapy, impact on pulmonary endpoints), diuretics continue to be used in clinical practice (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23478874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23478874'])">Ref</a></span>). Infants: Oral: 1.5 mg/kg/dose every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2677293','lexi-content-ref-2926575','lexi-content-ref-10693099','lexi-content-ref-21901679']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2677293','lexi-content-ref-2926575','lexi-content-ref-10693099','lexi-content-ref-21901679'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6b3bf4fb-d61c-4d60-acaa-a34bb1a9f68a">Edema</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Edema (diuresis): </b>Limited data available: Infants, Children, and Adolescents: Oral: Initial: 1 to 3 mg/kg/day divided every 6 to 24 hours; titrate as needed; reported maximum daily dose range: 4 to 6 mg/kg/<b>day</b> in divided doses every 6 to 12 hours or 400 mg/<b>day</b>, whichever is less (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21464748','lexi-content-ref-Kliegman.2016','lexi-content-ref-12734047','lexi-content-ref-16898855']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21464748','lexi-content-ref-Kliegman.2016','lexi-content-ref-12734047','lexi-content-ref-16898855'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b> Limited data available: Infants, Children, and Adolescents: Oral: Initial: 1 mg/kg/day divided every 12 to 24 hours; titrate as needed up to a maximum daily dose: 3.3 mg/kg/<b>day</b> or 100 mg/<b>day</b>, whichever is less (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15286277','lexi-content-ref-Park.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15286277','lexi-content-ref-Park.2014'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e046589e-da70-4374-9e6a-3e0ab4c6a9c5">Primary aldosteronism, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary aldosteronism (caused by adrenal hyperplasia), treatment</b>: Limited data available: Infants, Children, and Adolescents: Oral: 1 to 3 mg/kg/day; maximum daily dose: 100 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.2016'])">Ref</a></span>)</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51160254"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; spironolactone is substantially excreted by the kidney; use with caution; monitor serum potassium closely. The following recommendations have been suggested: In pediatric patients with mild to moderate failure, consider extended dosing interval (eg, every 12 to 24 hours) and avoid use in severe renal impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16898855']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16898855'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51160255"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; minor alterations of fluid and electrolyte balance may precipitate hepatic coma.</p></div>
<div class="block doa drugH1Div" id="F222866"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9943" href="/d/html/9943.html" rel="external">see "Spironolactone: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Suspension is <b>not</b> therapeutically equivalent to tablets. Suspension results in 15% to 37% higher serum concentration compared to tablets. Doses of suspension &gt;100 mg may result in higher than expected serum concentrations. In patients requiring &gt;100 mg/dose, use tablets only.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a88f723a-5453-4354-a4a0-47d649ee72c3">Acne vulgaris, females, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris, females, moderate to severe (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Tablet: Oral:</b> Initial: 25 to 50 mg/day in 1 to 2 divided doses; titrate as needed based on response and tolerability to a usual effective dose of 50 to 100 mg/day in 1 to 2 divided doses; maximum dose: 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386','lexi-content-ref-6235834','lexi-content-ref-Graber.2018','lexi-content-ref-2943311','lexi-content-ref-10954662','lexi-content-ref-15752283']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386','lexi-content-ref-6235834','lexi-content-ref-Graber.2018','lexi-content-ref-2943311','lexi-content-ref-10954662','lexi-content-ref-15752283'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b6fb7ac1-bbc8-410c-a521-e75c574154a6">Ascites due to cirrhosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ascites due to cirrhosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Generally used in combination with furosemide, but may be used as monotherapy for patients with hypokalemia. For combination therapy, a dosing ratio of spironolactone 100 mg to furosemide 40 mg should generally be maintained, but can be adjusted for electrolyte abnormalities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23463403','lexi-content-ref-Runyon.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23463403','lexi-content-ref-Runyon.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Tablet: Oral:</b> Initial: 100 mg once daily; titrate every 3 to 5 days based on response and tolerability; usual maximum dose: 400 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23463403','lexi-content-ref-Runyon.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23463403','lexi-content-ref-Runyon.2020'])">Ref</a></span>). For small-volume ascites in patients who weigh ≤50 kg, some experts recommend a starting dose of 50 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Runyon.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Runyon.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c17edbb-5896-4374-a116-179eac559565">Hair loss, female pattern</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hair loss, female pattern (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use as an adjunctive agent or as alternative monotherapy in patients who have inadequate response to or who cannot take preferred therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32259535','lexi-content-ref-34352345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32259535','lexi-content-ref-34352345'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Tablet: Oral:</b> Initial: 50 mg/day in 1 or 2 divided doses; if tolerated after 2 to 4 weeks, increase to 100 mg/day in 1 or 2 divided doses. If insufficient response after 6 months, may further increase dose up to 200 mg/day in 1 or 2 divided doses; usual effective dose: 100 to 200 mg/day. Treatment for at least 6 to 12 months is recommended for clinical benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32259535','lexi-content-ref-34352345','lexi-content-ref-McMichael.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32259535','lexi-content-ref-34352345','lexi-content-ref-McMichael.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="86fd017b-f098-427e-b843-c16a24638f11">Heart failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> When initiating therapy, verify the following: serum potassium &lt;5 mEq/L <b>and</b> serum creatinine ≤2.5 mg/dL in men and ≤2 mg/dL in women <b>or</b> eGFR &gt;30 mL/minute/1.73 m<sup>2 </sup>. If patient develops hyperkalemia or kidney function worsens, reduce the dose, change to every-other-day dosing, or discontinue therapy; assess for other causes of hyperkalemia before permanent discontinuation. If serum potassium cannot be maintained &lt;5.5 mEq/L, discontinue therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33446410','lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33446410','lexi-content-ref-35363499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Heart failure with preserved ejection fraction (off-label use)</i>:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For use in patients with symptomatic heart failure with preserved ejection fraction (HFpEF) (≥50%) who have an elevated serum natriuretic peptide level or have been hospitalized for heart failure in the last 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-24716680']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-24716680'])">Ref</a></span>). Some experts are more conservative regarding serum potassium for patients with HFpEF. They recommend initiating therapy or uptitrating the dose only if serum potassium is ≤4.7 mEq/L and eGFR is ≥30 mL/minute/1.73 m<sup>2</sup>. They recommend dose reduction or discontinuation if serum potassium is &gt;5 mEq/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Borlaug.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Borlaug.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Tablet: Oral:</b> Initial: 12.5 mg once daily; may double the dose every 2 to 4 weeks if serum potassium and kidney function are stable, up to a maximum target dose of 50 mg/day in 1 or 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-Borlaug.2020','lexi-content-ref-24716680']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-Borlaug.2020','lexi-content-ref-24716680'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Heart failure with reduced ejection fraction</i>: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Should be considered for use in patients with symptomatic (New York Heart Association class II to IV) heart failure with reduced ejection fraction (HFrEF) (≤40%) as part of an optimal medical regimen for HFrEF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Tablet: Oral:</b> Initial: 12.5 to 25 mg once daily; may double the dose every 4 weeks if serum potassium and kidney function are stable, up to a maximum target dose of 50 mg/day in 1 to 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-10471456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-10471456'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Suspension: Oral:</b> Initial: 10 to 20 mg once daily. Consider a starting dose of 10 mg once daily in patients at increased risk of hyperkalemia. May titrate to 37.5 mg once daily if serum potassium and kidney function are stable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-Colucci.2019','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-Colucci.2019','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Post-myocardial infarction, complicated by reduced ejection fraction (off-label use):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Should be considered for use following acute myocardial infarction (MI) in patients with left ventricular ejection fraction ≤40% plus symptoms of heart failure or diabetes. Use in addition to other pharmacologic therapies post MI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304','lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304','lexi-content-ref-35363499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Tablet: Oral:</b> Initial: 12.5 to 25 mg once daily; may double the dose every 4 weeks if serum potassium and kidney function are stable, up to a maximum target dose of 50 mg/day in 1 to 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Suspension: Oral:</b> Initial: 10 to 20 mg once daily. Consider a starting dose of 10 mg once daily in patients at increased risk of hyperkalemia. May titrate to 37.5 mg once daily if serum potassium and kidney function are stable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-Colucci.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-Colucci.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b0f5f625-dcc5-4b72-bd51-b2e34d2a16dc">Hirsutism, females</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hirsutism, females (alternative agent) (off-label use):</b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Typically given in addition to oral contraceptives (OCs) if inadequate response to OCs is observed after 6 months. May be considered as initial therapy for females who cannot conceive or who are using reliable contraception (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barbieri.2019','lexi-content-ref-29522147']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barbieri.2019','lexi-content-ref-29522147'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Tablet: Oral:</b> Initial: 50 mg twice daily; may increase to 100 mg twice daily as needed. Assess response at 6-month intervals before adjusting dose, adding additional agents, or switching to alternative therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barbieri.2019','lexi-content-ref-29522147']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barbieri.2019','lexi-content-ref-29522147'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="77f3beb6-ef12-4d8d-92ff-3a67049ecce5">Hormone therapy for transgender females, assigned male at birth</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hormone therapy for transgender females, assigned male at birth (adjunctive agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Tablet: Oral:</b> Initial: 25 mg once or twice daily in combination with other appropriate agents. Increase at 1-week intervals based on response and tolerability to a usual dose of 100 to 300 mg/day in 2 divided doses; maximum dose: 400 mg/day. Adjust dose with a goal of suppressing serum testosterone levels into the normal range for females (&lt;50 ng/dL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Deutsch.2016','lexi-content-ref-29320642','lexi-content-ref-2540730']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Deutsch.2016','lexi-content-ref-29320642','lexi-content-ref-2540730'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f0c92d9-ad08-4643-a848-3296ddf5258e">Hypertension, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>: Not recommended for initial management but may be considered as additional therapy for resistant hypertension in patients who do not respond adequately to combination therapy with preferred agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-29356711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-29356711'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Tablet: Oral:</b> Initial: 25 mg once daily; titrate as needed after ~2 to 4 weeks based on response and tolerability up to 100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-29356711','lexi-content-ref-24107738','lexi-content-ref-26414968']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-29356711','lexi-content-ref-24107738','lexi-content-ref-26414968'])">Ref</a></span>). Some experts recommend a starting dose of 12.5 mg once daily and generally do not exceed 50 mg once daily in the absence of primary aldosteronism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brook.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brook.1'])">Ref</a></span>). Patients with severe asymptomatic hypertension and no signs of acute end organ damage should be evaluated for medication titration within 1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mann.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mann.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Suspension: Oral:</b> Initial: 20 mg/day in 1 or 2 divided doses; titrate as needed after ~2 to 4 weeks based on response and tolerability up to 75 mg/day in 1 or 2 divided doses. Patients with severe asymptomatic hypertension and no signs of acute end organ damage should be evaluated for medication titration within 1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mann.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mann.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2077fe7f-3b26-4f56-b690-0a9b9ad8a8ea">Primary aldosteronism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary aldosteronism:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Tablet: Oral:</b> Initial: 12.5 to 25 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26934393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26934393'])">Ref</a></span>); gradually titrate to the lowest effective dose; usual maximum dose: 400 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Young.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Young.2019'])">Ref</a></span>). For surgical candidates, the last dose should be administered the day of surgery; discontinue spironolactone on postoperative day 1 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26934393','lexi-content-ref-Young.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26934393','lexi-content-ref-Young.2019'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991398"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Use with caution; monitor potassium prior to initiating spironolactone and closely during therapy. In circumstances where treatment with spironolactone is considered necessary, interventions such as dietary counseling on a low potassium diet, loop diuretics, sodium bicarbonate to correct metabolic acidosis, and prescribing daily GI cation exchangers (eg, patiromer, zirconium cyclosilicate) have been utilized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31533906','lexi-content-ref-26172895','lexi-content-ref-31110051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31533906','lexi-content-ref-26172895','lexi-content-ref-31110051'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Tablet:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Ascites due to cirrhosis; hypertension; primary aldosteronism:</b> There are no specific dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Heart failure:</b></p>
<p style="text-indent:-2em;margin-left:8em;">eGFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No initial dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">eGFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: Initial: 12.5 mg once daily or every other day; may double the dose every 4 weeks if serum potassium remains &lt;5 mEq/L and kidney function is stable, up to a maximum target dose of 25 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23741058']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23741058'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23741058']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23741058'])">Ref</a></span>); heart failure clinical trials excluded patients with serum creatinine ≥2.5 mg/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10471456','lexi-content-ref-24716680']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10471456','lexi-content-ref-24716680'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Suspension:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Ascites due to cirrhosis; hypertension:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Heart failure:</b></p>
<p style="text-indent:-2em;margin-left:8em;">eGFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No initial dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">eGFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: Initial: 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Use not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23741058']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23741058'])">Ref</a></span>); heart failure clinical trials excluded patients with serum creatinine ≥2.5 mg/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10471456','lexi-content-ref-24716680']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10471456','lexi-content-ref-24716680'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27797886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27797886'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Tablet:</b> Not routinely recommended, but 2 small trials have demonstrated the safety of spironolactone in patients with end-stage kidney disease receiving dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30473139','lexi-content-ref-30712923']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30473139','lexi-content-ref-30712923'])">Ref</a></span>), with a suggested maximum of 25 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30473139']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30473139'])">Ref</a></span>). Start at lowest initial dose (eg, 12.5 mg daily or every other day) and only utilize if benefits outweigh the risks, potassium is well-controlled, and patients can be monitored closely for hyperkalemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed given high degree of protein binding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Tablet:</b> Not routinely recommended, but 2 small trials have demonstrated the safety of doses up to 25 mg once daily in patients receiving peritoneal dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31419271','lexi-content-ref-24335969']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31419271','lexi-content-ref-24335969'])">Ref</a></span>). Start at lowest initial dose (eg, 12.5 mg daily or every other day) and only utilize if benefits outweigh the risks, potassium is well-controlled, and patients can be monitored closely for hyperkalemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988599"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling; initiate with low dose and titrate slowly (cirrhosis). Use with caution; minor alterations of fluid and electrolyte balance may precipitate hepatic coma.</p></div>
<div class="block arsc drugH1Div" id="F54485792"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Gynecomastia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Spironolactone may cause <b>gynecomastia</b> in patients of any age that may affect one or both breasts (typically both) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15860966']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15860966'])">Ref</a></span>). Gynecomastia is usually reversible following discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19648382','lexi-content-ref-25827472']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19648382','lexi-content-ref-25827472'])">Ref</a></span>). Eplerenone, which is associated with a lower risk of gynecomastia, may be considered if continued aldosterone antagonist therapy is required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28090229','lexi-content-ref-12668699']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28090229','lexi-content-ref-12668699'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; due to decreased androgen production, inhibition of androgen receptor binding, displacement of estradiol from sex hormone-binding globulin and enhanced peripheral conversion of testosterone to estradiol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19648382','lexi-content-ref-15860966','lexi-content-ref-907238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19648382','lexi-content-ref-15860966','lexi-content-ref-907238'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; may occur after 1 to 2 months to over a year of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (eg, ≥150 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19648382','lexi-content-ref-25827472']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19648382','lexi-content-ref-25827472'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19648382','lexi-content-ref-25827472']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19648382','lexi-content-ref-25827472'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperkalemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Spironolactone may cause reversible <b>hyperkalemia</b>, which may result in hospitalization and in some cases death (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15295047','lexi-content-ref-24812304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15295047','lexi-content-ref-24812304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; related to the pharmacologic action. Competes with aldosterone for binding to the mineralocorticoid receptor, thereby inhibiting the exchange of sodium for potassium in the distal convoluted renal tubule and preventing potassium excretion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; usually occurs within 4 weeks of initiation or dose titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24812304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24812304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24812304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24812304'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15632880','lexi-content-ref-31360748','lexi-content-ref-24812304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15632880','lexi-content-ref-31360748','lexi-content-ref-24812304'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Excessive potassium intake (eg, potassium supplements, potassium-containing salt substitutes)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other medications that increase serum potassium (eg, angiotensin-converting enzyme [ACE] inhibitors, angiotensin-receptor blockers, drospirenone, nonsteroidal anti-inflammatory drugs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15632880','lexi-content-ref-24812304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15632880','lexi-content-ref-24812304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of larger doses of ACE inhibitors (eg, lisinopril ≥10 mg daily in adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23741058']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23741058'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Heart failure (especially patients receiving higher doses and patients with diabetes mellitus, higher baseline serum potassium levels, and worse New York Heart Association functional class) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15632880','lexi-content-ref-24812304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15632880','lexi-content-ref-24812304'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F222826"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Endocrine &amp; metabolic: Gynecomastia (9%; up to 52% in patients receiving high doses [eg, ≥150 mg/day]) (Haynes 2009; Jeunemaitre 1987; Nuttall 2015; Prisant 2005)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Chloasma, erythematous maculopapular rash, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido, hyperglycemia, hypocalcemia, hypomagnesemia, hyponatremia, hypovolemia, irregular menses, postmenopausal bleeding</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps, diarrhea, gastritis, gastrointestinal hemorrhage, gastrointestinal ulcer, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction, mastalgia, nipple pain</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, drug reaction with eosinophilia and systemic symptoms</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia, confusion, dizziness, drowsiness, headache, lethargy</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lower limb cramp</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Kidney failure, kidney impairment</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea (Levitt 1970), hyperkalemia (Huang 2005; Shah 2005), hyperuricemia (Ben Salem 2017), metabolic acidosis (in patients with cirrhosis) (Feinfeld 1978; Gabow 1979)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Ovarian cyst (in a premature neonate) (Vachharajani 2001)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Whitling 1997)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Gout (Ben Salem 2017)</p></div>
<div class="block coi drugH1Div" id="F222842"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hyperkalemia; Addison disease; concomitant use with eplerenone.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Hypersensitivity to spironolactone or any component of the formulation; acute kidney insufficiency; severe kidney impairment (eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>); anuria; concomitant use with heparin or low molecular weight heparin; pregnancy; breastfeeding.</p></div>
<div class="block war drugH1Div" id="F222823"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fluid/electrolyte imbalance: Fluid and electrolyte imbalance (eg, hypomagnesemia, hyponatremia, hypocalcemia, hyperglycemia, hyperkalemia) may occur. Patients with heart failure, kidney disease, or cirrhosis may be particularly susceptible. Monitor and correct electrolyte disturbances; adjust dose to avoid dehydration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumorigenic: Shown to be a tumorigen in chronic toxicity animal studies. Recent retrospective and observational studies do not suggest an increased risk of prostate or breast cancer (McKenzie 2016; Rozner 2020; Sabatier 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal vein catheterization: Discontinue use prior to adrenal vein catheterization.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: When evaluating a heart failure patient for spironolactone treatment, eGFR should be &gt;30 mL/minute/1.73 m<sup>2</sup> or creatinine should be ≤2.5 mg/dL (men) or ≤2 mg/dL (women) with no recent worsening and potassium &lt;5 mEq/L with no history of severe hyperkalemia. Discontinue therapy if serum potassium cannot be maintained &lt;5.5 mEq/L or if kidney function worsens. Consider the entire medical regimen and other potential causes of hyperkalemia (AHA/ACC/HFSA [Heidenreich 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>
<b>Other warnings/precautions</b>:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Suspension: Suspension is <b>NOT</b> therapeutically equivalent to tablets. In patients requiring &gt;100 mg/dose, use tablets (&gt;100 mg/dose of suspension may result in spironolactone concentration higher than expected).</p></div>
<div class="block foc drugH1Div" id="F222835"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">CaroSpir: 25 mg/5 mL (5 mL) [contains saccharin sodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">CaroSpir: 25 mg/5 mL (118 mL, 473 mL) [contains saccharin sodium; banana flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg/5 mL (118 mL, 473 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aldactone: 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aldactone: 50 mg, 100 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg</p></div>
<div class="block geq drugH1Div" id="F222819"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F222845"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (CaroSpir Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/5 mL (per mL): $4.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Spironolactone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/5 mL (per mL): $3.80 - $4.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Aldactone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $3.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $5.71</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $9.57</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Spironolactone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.19 - $0.46</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.81 - $0.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $1.42 - $1.43</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868285"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aldactone: 25 mg, 100 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 100 mg</p></div>
<div class="block exp drugH1Div" id="F222840"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>5 mg/mL Oral Suspension (ASHP Standard Concentration) </b>(ASHP 2017)</p>
<p style="text-indent:-2em;margin-left:2em;">A 5 mg/mL oral suspension may be made with tablets. Crush twelve 50 mg tablets in a mortar and reduce to a fine powder. Add small portions of distilled water and mix to a uniform paste; mix while adding cherry syrup to <b>almost</b> 120 mL; transfer to a calibrated glass bottle, rinse mortar with cherry syrup, and add quantity of cherry syrup sufficient to make 120 mL. Label "shake well" and "refrigerate." Stable for 28 days at room temperature or refrigerated (Mathur 1989).</p>
<div class="reference">Mathur LK, Wickman A. Stability of extemporaneously compounded spironolactone suspensions. <i>Am J Hosp Pharm.</i> 1989;46(10):2040-2042.<span class="pubmed-id">2816959</span></div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>1 mg/mL Oral Suspension</b></p>
<p style="text-indent:-2em;margin-left:2em;">A 1 mg/mL oral suspension may be made with tablets. Crush ten 25 mg tablets in a mortar and reduce to a fine powder. Add a small amount of purified water and soak for 5 minutes; add 50 mL 1.5% carboxymethylcellulose, 100 mL syrup NF, and mix to a uniform paste; mix while adding purified water in incremental proportions to <b>almost</b> 250 mL; transfer to a calibrated bottle, rinse mortar with purified water, and add quantity of purified water sufficient to make 250 mL. Label "shake well." Stable for 3 months at room temperature or refrigerated (Nahata 1993).</p>
<div class="reference">Nahata MC, Morosco RS, and Hipple TF, "Stability of Spironolactone in an Extemporaneously Prepared Suspension at Two Temperatures," <i>Ann Pharmacother</i>. 1993, 27(10):1198-9.<span class="pubmed-id">8251687</span></div>
<p style="text-indent:-2em;margin-left:2em;">
<b>25 mg/mL Oral Suspension</b></p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">A 25 mg/mL oral suspension may be made with tablets and either a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of Ora-Sweet SF and Ora-Plus. Crush one-hundred-twenty 25 mg tablets in a mortar and reduce to a fine powder. Add small portions of chosen vehicle and mix to a uniform paste; mix while adding vehicle in incremental proportions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Store in amber bottles; label "shake well" and "refrigerate." Stable for 60 days refrigerated (Allen 1996).</p>
<div class="reference">Allen LV Jr and Erickson MA 3rd, "Stability of Ketoconazole, Metolazone, Metronidazole, Procainamide Hydrochloride, and Spironolactone in Extemporaneously Compounded Oral Liquids," <i>Am J Health Syst Pharm</i>. 1996, 53(17):2073-8.<span class="pubmed-id">8870895</span></div>
</div>
<div class="block admp drugH1Div" id="F52613878"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be taken with or without food; however, consistent administration with or without food is preferred to minimize fluctuations in drug exposure.</p></div>
<div class="block adm drugH1Div" id="F50591704"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:2em;">Tablet: Administer with or without food; however, administer consistently with respect to food.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension: Shake well before administering dose. Administer with or without food; however, administer consistently with respect to food.</p></div>
<div class="block hazard drugH1Div" id="F49132823"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F222855"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Tablet: Store below 25°C (77°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block usep drugH1Div" id="F53568937"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Aldactone and similar generics: Management of edema and sodium retention associated with heart failure unresponsive to other therapies, cirrhosis of liver accompanied by edema and/or ascites, or nephrotic syndrome unresponsive to other therapies; increase survival and to reduce hospitalization for severe heart failure (New York Heart Association class III to IV) when used in addition to standard therapy; management of hypertension unresponsive to other therapies; treatment of hypokalemia unresponsive to other therapies; prophylaxis of hypokalemia in patients taking digitalis; diagnose primary hyperaldosteronism by therapeutic trial; short-term preoperative treatment of primary hyperaldosteronism; long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery; and long-term maintenance therapy for bilateral micro- or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism) (All indications: FDA approved in adults)</p>
<p style="text-indent:-2em;margin-left:2em;">CaroSpir: Treatment of edema associated with cirrhosis of liver, increase survival and to reduce hospitalization for severe heart failure (New York Heart Association class III to IV) when used in addition to standard therapy, and management of hypertension unresponsive to other therapies (All indications: FDA approved in adults)</p></div>
<div class="block mst drugH1Div" id="F222916"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Aldactone may be confused with Aldactazide.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Diuretics are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Aldactone: Brand name for spironolactone [US, Canada, multiple international markets], but also the brand name for potassium canrenoate [Austria, Czech Republic, Germany, Hungary, Poland].</p>
<p style="text-indent:-2em;margin-left:4em;">Aldactone [US, Canada, multiple international markets] may be confused with Aldomet brand name for methyldopa [multiple international markets].</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300079"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F222828"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abiraterone Acetate: Spironolactone may diminish the therapeutic effect of Abiraterone Acetate.  Management: Consider alternatives to the combined use of spironolactone and abiraterone. If combined, monitor the clinical response to abiraterone closely, looking specifically for signs of clinical failure and/or disease progression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists: Spironolactone may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ammonium Chloride: Potassium-Sparing Diuretics may enhance the adverse/toxic effect of Ammonium Chloride. Specifically the risk of systemic acidosis. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aspirin: May diminish the therapeutic effect of Spironolactone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholestyramine Resin: May enhance the adverse/toxic effect of Spironolactone. Specifically, the risks of developing metabolic acidosis and hyperkalemia may be elevated with this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciprofloxacin (Systemic): Spironolactone may enhance the arrhythmogenic effect of Ciprofloxacin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: Spironolactone may diminish the diagnostic effect of Cosyntropin.  Management: Patients receiving spironolactone should omit their pre-test dose on the day selected for cosyntropin testing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of CycloSPORINE (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C8 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors): Spironolactone may increase the serum concentration of CYP2C8 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors): Spironolactone may increase the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diacerein: May enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Spironolactone may increase the serum concentration of Digoxin. Spironolactone (and/or its metabolites) may also interfere with the assays used to determine Digoxin concentrations, falsely increasing or decreasing Digoxin concentrations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fludrocortisone: May diminish the therapeutic effect of Mineralocorticoid (Aldosterone) Receptor Antagonists. Mineralocorticoid (Aldosterone) Receptor Antagonists may diminish the therapeutic effect of Fludrocortisone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Management: Monitor serum potassium concentrations closely. The spironolactone Canadian product monograph lists its combination with heparin or low molecular weight heparins as contraindicated.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Potassium-Sparing Diuretics may increase the serum concentration of Lithium. Potassium-Sparing Diuretics may decrease the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitotane: Spironolactone may decrease the serum concentration of Mitotane. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: May enhance the adverse/toxic effect of Diuretics. Opioid Agonists may diminish the therapeutic effect of Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Diuretics may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Salts: May enhance the hyperkalemic effect of Spironolactone.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of other Potassium-Sparing Diuretics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: May enhance the hyperkalemic effect of Spironolactone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F222856"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food increases the bioavailability of unmetabolized spironolactone by ~90% to 95%.</p></div>
<div class="block dic drugH1Div" id="F222848"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Administration with food increases the bioavailability of spironolactone. Excessive potassium intake (eg, salt substitutes, low-salt foods, bananas, nuts) should be avoided.</p></div>
<div class="block rep_considerations drugH1Div" id="F54046894"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Spironolactone is associated with dose-dependent menstrual irregularities (AAD [Zaenglein 2016]; ES [Funder 2016]; ES [Martin 2018]; Kallistratos 2018). Some guidelines recommend use of combination oral contraception in premenopausal patients to regulate menses and prevent pregnancy (AAD [Zaenglein 2016], ES [Martin 2018]). Decreasing the dose or switching to an alternative mineralocorticoid receptor antagonist may be appropriate for some indications (ES [Funder 2016]; Kallistratos 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Spironolactone is associated with dose-dependent erectile dysfunction (AAD [Zaenglein 2016]; ES [Funder 2016]; ES [Martin 2018]; Kallistratos 2018). Decreasing the dose or switching to an alternative mineralocorticoid receptor antagonist may be appropriate for some indications (ES [Funder 2016]; Kallistratos 2018). The antiandrogen blocking activity of spironolactone results in decreased spontaneous erections, sperm production, and testicular volume in transgender patients undergoing feminizing therapy (ES [Hembree 2017]).</p>
<p style="text-indent:0em;margin-top:2em;">Patients taking spironolactone for primary aldosteronism (PA) who are planning to become pregnant should be switched to other agents prior to conception when possible (Forestiero 2022). Patients who require use of spironolactone for the treatment of PA should use the lowest effective dose prior to a planned pregnancy, then stop treatment once their pregnancy is confirmed (Riester 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be continued in patients trying to conceive. The use of mineralocorticoid receptor antagonists is not recommended for the treatment of chronic hypertension in pregnant patients (ACOG 2019). Consider transitioning to an agent preferred for use during pregnancy in patients planning to become pregnant (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Patients with heart failure who are planning to become pregnant should discontinue mineralocorticoid receptor antagonists prior to conception (AHA/ACC/HFSA [Heidenreich 2022]).</p></div>
<div class="block pri drugH1Div" id="F222846"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Spironolactone crosses the placenta (ESC [Regitz-Zagrosek 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to spironolactone during the period of embryogenesis may cause feminization of a male fetus (limited human data; Liszewski 2019). High doses late in pregnancy may be associated with intrauterine growth restriction (Riester 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019). Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment of chronic hypertension during pregnancy is indicated, the use of mineralocorticoid receptor antagonists is generally not recommended (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Data specific to the treatment of primary aldosteronism (PA) in pregnancy are limited. Patients with PA should stop spironolactone before conception or during the first trimester once the pregnancy is confirmed (Riester 2015). If spironolactone is stopped and PA is not controlled, agents other than spironolactone are recommended for the adjunctive treatment of PA during pregnancy (Forestiero 2022; Sanga 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Heart failure in pregnancy is associated with adverse maternal and fetal outcomes, including premature birth, infants born small for gestational age, and increased risk of maternal and fetal death (Bright 2021). When treatment of heart failure during pregnancy is needed, the use of an agent other than a mineralocorticoid receptor antagonist is recommended (AHA/ACC/HFSA [Heidenreich 2022]; ESC [Regitz-Zagrosek 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Case reports describe the use of potassium-sparing diuretics such as spironolactone for the adjunctive treatment of Gitleman syndrome during pregnancy (Calò 2012; Moustakakis 2012; Shahzad 2019).</p></div>
<div class="block mopp drugH1Div" id="F53568923"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure, serum potassium, sodium, calcium (neonates) and renal function (baseline, periodically during therapy), fluid balance, bodyweight (daily: neonates, infants)</p></div>
<div class="block pha drugH1Div" id="F222822"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Competes with aldosterone for receptor sites in the distal renal tubules, increasing sodium chloride and water excretion while conserving potassium and hydrogen ions; may block the effect of aldosterone on arteriolar smooth muscle as well</p></div>
<div class="block phk drugH1Div" id="F222841"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Suspension results in 15% to 37% higher serum concentration compared to the tablet; doses of suspension &gt;100 mg may result in higher spironolactone concentrations than expected.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Tablet: 2 to 3 days</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: High-fat/-calorie meal increased the bioavailability of spironolactone ~90%.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;90%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Rapid and extensive; hepatic to multiple metabolites, including active metabolites canrenone, 7-alpha-spirolactone, and 6-beta-hydroxy-7-alpha</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: Spironolactone: 1.4 hours; Canrenone: 16.5 hours (terminal); 7-alpha-spirolactone: 13.8 hours (terminal)</p>
<p style="text-indent:-2em;margin-left:4em;">Suspension: Spironolactone: 1 to 2 hours; Canrenone, 7-alpha-spirolactone, and 6-beta-hydroxy-7-alpha: 10 to 35 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum:</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: 2.6 to 4.3 hours (primarily as active metabolites)</p>
<p style="text-indent:-2em;margin-left:4em;">Suspension: Spironolactone: 0.5 to 1.5 hours; Canrenone: 2.5 to 5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (primarily as metabolites) and bile (secondary)</p></div>
<div class="block phksp drugH1Div" id="F51221464"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Terminal half-life is increased in patients with cirrhotic ascites.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F222849"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Noractone | Spiroctan</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aldactone a | Espimax | Espironolactona | Espironolactona northia | Espironolactona vannier | Expal | Lanx | Modulactone | Normital | Osiren | Rediun e</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Aldopur | Spirobene | Spirohexal | Spirono | Spironolacton</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Spiractin | Spironolactone mylan</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Aldactone a | Aldaton p | Inospiron | Pilactone | Spiretic | Spirocard | Spiron | Verospirone</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Docspirono | Nefrotone | Spironolactone eurogenerics | Spironolactone sandoz | Spirotop | Uractone</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Spinox | Spirotone</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Spironolacton | Spironolacton accord | Spylacton</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Aldosterin | Diacqua | Espirilona | Espirolona | Espironolactona | Spiroctan</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Primacton | Xenalon</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Spinox</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Alizar | Cardactona | Espironolactona</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">She xin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Doxiclat | Espirolan | Espironolactona | Espironolactona mk | Kespirona</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Spirolone | Verospiron | Xenalon</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Aldopur | Aquareduct | Duraspiron | Jenaspiron | Osyrol | Spiro | Spiro-tablinen | Spirobeta | Spirogamma | Spirono | Spironolacton | Spironolacton 1A Pharma | Spironolacton Accedo | Spironolacton al | Spironolacton Aristo | Spironolacton Dura | Spironolacton Heumann | Spironolacton hexal | Spironolacton Ratiopharm | Verospiron</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Blime | Cardiatone | Drimux a | Espirocor | Espirolam | Espironolactona | Espironolactona LAM | Espironolactona Mamey | Indurit | Lanx | Spiro-K | Spirolactona | Sprenol</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Cardactona | Dialon | Espironolactona | Spirolon</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Spiresis | Spirix | Spironolacton accord | Spironolacton Ratiopharm | Spironolacton-ratipharm | Uracton | Verospiron</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Aldactone a | Antagerone | Epilactone | Potasave | Potaspirono | Spectone</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Aldactone a | Espironolacton | Espironolacton accord | Espironolactona alter</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Spiractin | Spiracton | Spiresis | Spiridon | Spirix | Spironolactone orion</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Flumach | Practon | Spironolactone actavis | Spironolactone arrow | Spironolactone biogaran | Spironolactone Cristers | Spironolactone G Gam | Spironolactone GNR | Spironolactone Irex | Spironolactone Ivax | Spironolactone rpg | Spironolactone Teva | Spironolactone zydus | Spironone | Spirophar</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Abbolactone | Aldactone | Diatensec | Laractone | Spiretic | Spiroctan | Spirolone | Spironolactone A L | Spironolactone aps | Spironolactone cox | Spironolactone dc | Spirospare</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Rocanol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Euro spiro | Spironolactone actavis | Spiroton | Uractonum</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Aldactone</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Huma-spiroton | Spirolone | Spiron | Verospiron</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Carpiaton | Idrolattone | Letonal | Spirola | Spirolacton</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Aldactone</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Aldospirone | Spironol</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Spilactone</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Uractone</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Aldoram | Noractone | Unilactone</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Adultmin | Aldactone a | Alexan | Almatol | Alpamed | Altibon | Apinorakuton | Aporasnon | Apotax | Bastolebon a | Carditan | Demisron | Dira kaken | Dira merck hoei | Diropar | Elmion | Hokulaton | Hypazon | Lacalmin | Lactopalm | Macacy a | Merlactone | Merlactone kobayashi kao | Nefurofan | Noidouble | Osyrol | Penantin | Pirodactone | Pirolacton | Pirolacton taiyo | Rakudeen | Rakudeen tsuruhara | Resacton | Spilactone | Suracton | Tarolactone | Uretoron | Urodactone | Urusonin | Youlactone</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Lactone | Spirolac | Spirolon</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Sincomen | Spiracton | Spirodacton | Unilacton</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Aldactone a</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Aldactone</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Spirix | Spirolakton | Spirolone | Spironolacton | Spironolacton accord | Spironolacton orion | Spironolactone accord | Uractone | Verospiron</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Docspirono | Uractone</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Spiridon | Spirix | Spirogamma | Spirolakton | Spirolone | Spironolacton | Spironolacton accord | Uracton | Verospiron | Xenalon</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Aldactone</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Aldactone a | Androlectona | Biolactona | Espironolactona | Nolasque | Quimolactona | Vivitar</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Spirolon</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Alpadactone | Curelactone | Labkon | Salemm | Spinotone | Spiropath spironolactone</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Spironolacton | Spironolacton A | Spironolacton accord | Spironolacton prolepha | Spironolacton Ratiopharm</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Spirix | Spironolacton aurobindo | Spironolactone accord | Spironolactone arrow | Spironolactone orion | Spiropal</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Spirotone</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Aldactone a | Diurec | Espirone | Espironolactona | Espironolactona Fmndtria | Spirone</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Aldactin | Aldactone | Aldactone a | Atagon | Beralactone | Diulactone | Epheral | Golactone | Lactone | Spinofar | Spirofar | Spiros | Spitone</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Aldactone a</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Aldactone a | Finospir | Ismian | Polspiron | Spiridon | Spironol | Spironolacton | Verospiron</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Carospir</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Aldonar | Espironolactona | Espironolactona mylan | Nefrolactona</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Aldoxol | Aldoxol forte | Alizar | Drimux a | Espironolactona dallas | Espironolactona heisecke | Hidro max | Indurit | Indurit forte | Nebular | Terotrom</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Aldactone</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Alspiron | Verospiron</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Spirix | Spironol | Spironolacton | Spironolacton Medisorb | Spironolacton velfarm | Vero spironolactone | Verospilactone | Verospiron</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Aldactone a | Noractone</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Spiridon | Spirix | Spiroctan | Spironolactone accord | Spironolactone orion | Spironolakton nordic | Spironolakton nycomed | Spironolakton pfizer | Spiroscand</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Spiridon | Spirolon | Uractonum</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Xenalon</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Medospir | Spironolactone accord | Verospiron</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Altone | Hyles | Pondactone | S tone | Spiro | Spirone | Spironex | Tevaspirone</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Noractone</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Aldactone a | Spylacton</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Aldactin | Aldactone | Brislactone | Macacy a | Melabis a | Shyylouh | Skyton | Spirolon | Spiron | Spirotone | Subitong</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Spirix | Spironol | Spironolacton | Spironolactonum Darnitsa | Verospiron</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Aldactone a | Espirolactona | Espironolactona</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Espironolactona | Spiroctan</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Domever | Entacron</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aldactone | Rolab-spironolactone | Sandoz spironolactone | Spiractin</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Lactone</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Aldactone</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.2017">
<a name="USP.2017"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31533906">
<a name="31533906"></a>Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet</i>. 2019;394(10208):1540-1550. doi:10.1016/S0140-6736(19)32135-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/31533906/pubmed" id="31533906" target="_blank">31533906</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2677293">
<a name="2677293"></a>Albersheim SG, Solimano AJ, Sharma AK, et al. Randomized, double-blind, controlled trial of long-term diuretic therapy for bronchopulmonary dysplasia. <i>J Pediatr</i>. 1989;115(4):615-620.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/2677293/pubmed" id="2677293" target="_blank">2677293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aldactone.2018.04">
<a name="Aldactone.2018.04"></a>Aldactone (spironolactone) [prescribing information]. New York, NY: Pfizer Labs; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aldactone.2015.07">
<a name="Aldactone.2015.07"></a>Aldactone (spironolactone) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULD; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 203: chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25260718">
<a name="25260718"></a>Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>J Am Coll Cardiol</i>. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi:10.1016/j.jacc.2014.09.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/25260718/pubmed" id="25260718" target="_blank">25260718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21524875">
<a name="21524875"></a>Aronow WS, Fleg JL, Pepine CJ, et al. ACC/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. <i>J Am Coll Cardiol</i>. 2011;57(20):2037-2114.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/21524875/pubmed" id="21524875" target="_blank">21524875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.2017">
<a name="ASHP.2017"></a>ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26172895">
<a name="26172895"></a>Bakris GL, Pitt B, Weir MR, et al.; AMETHYST-DN Investigators. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. <i>JAMA</i>. 2015;314(2):151-161. doi:10.1001/jama.2015.7446<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/26172895/pubmed" id="26172895" target="_blank">26172895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barbieri.2019">
<a name="Barbieri.2019"></a>Barbieri RL, Chang J. Management of hirsutism in premenopausal women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 29, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29522176">
<a name="29522176"></a>Barrionuevo P, Nabhan M, Altavar O, et al. Treatment options for hirsutism: a systematic review and network meta-analysis. <i>J Clin Endocrinol Metab</i>. 2018;103(4):1258-1264. doi:10.1210/jc.2017-02052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/29522176/pubmed" id="29522176" target="_blank">29522176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27338866">
<a name="27338866"></a>Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>Eur J Heart Fail</i>. 2016;18(9):1096-1105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/27338866/pubmed" id="27338866" target="_blank">27338866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29356711">
<a name="29356711"></a>Bazoukis G, Thomopoulos C, Tsioufis C. Effect of mineralocorticoid antagonists on blood pressure lowering: overview and meta-analysis of randomized controlled trials in hypertension. <i>J Hypertens</i>. 2018;36(5):987-994. doi:10.1097/HJH.0000000000001671<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/29356711/pubmed" id="29356711" target="_blank">29356711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27498351">
<a name="27498351"></a>Ben Salem C, Slim R, Fathallah N, Hmouda H. Drug-induced hyperuricaemia and gout. <i>Rheumatology (Oxford)</i>. 2017;56(5):679-688. doi:10.1093/rheumatology/kew293<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/27498351/pubmed" id="27498351" target="_blank">27498351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Borlaug.2020">
<a name="Borlaug.2020"></a>Borlaug BA, Colucci WS. Treatment and prognosis of heart failure with preserved ejection fraction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brook.1">
<a name="Brook.1"></a>Brook RD, Townsend RR. Treatment of resistant hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32259535">
<a name="32259535"></a>Burns LJ, De Souza B, Flynn E, Hagigeorges D, Senna MM. Spironolactone for treatment of female pattern hair loss. <i>J Am Acad Dermatol</i>. 2020;83(1):276-278. doi:10.1016/j.jaad.2020.03.087<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/32259535/pubmed" id="32259535" target="_blank">32259535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21999963">
<a name="21999963"></a>Calò LA, Caielli P. Gitelman's syndrome and pregnancy: new potential pathophysiological influencing factors, therapeutic approach and materno-fetal outcome. <i>J Matern Fetal Neonatal Med</i>. 2012;25(8):1511-1513. doi:10.3109/14767058.2011.629254<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/21999963/pubmed" id="21999963" target="_blank">21999963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Carospir.2017.08">
<a name="Carospir.2017.08"></a>Carospir (spironolactone) [prescribing information]. Farmville, NC: CMP Pharma Inc; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30473139">
<a name="30473139"></a>Charytan DM, Himmelfarb J, Ikizler TA, et al.; Hemodialysis Novel Therapies Consortium. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. <i>Kidney Int.</i> 2019;95(4):973-982. doi:10.1016/j.kint.2018.08.034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/30473139/pubmed" id="30473139" target="_blank">30473139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Colucci.2019">
<a name="Colucci.2019"></a>Colucci WS. Secondary pharmacologic therapy in heart failure with reduced ejection fraction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 2, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Deutsch.2016">
<a name="Deutsch.2016"></a>Deutsch MB. Guidelines for the primary and gender-affirming care of transgender and nonbinary people. Center of Excellence for Transgender Health. <a href="http://transhealth.ucsf.edu/trans?page=guidelines-home" target="_blank">http://transhealth.ucsf.edu/trans?page=guidelines-home</a>. Published June 17, 2016. Accessed January 14, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28090229">
<a name="28090229"></a>De Vecchis R, Cantatrione C, Mazzei D, Barone A, Maurea N. The Impact Exerted on Clinical Outcomes of Patients With Chronic Heart Failure by Aldosterone Receptor Antagonists: A Meta-Analysis of Randomized Controlled Trials. <i>J Clin Med Res</i>. 2017;9(2):130-142. doi:10.14740/jocmr2851w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/28090229/pubmed" id="28090229" target="_blank">28090229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eichenwald.2017">
<a name="Eichenwald.2017"></a>Eichenwald EC, ed. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2926575">
<a name="2926575"></a>Engelhardt B, Blalock WA, DonLevy S, Rush M, Hazinski TA. Effect of spironolactone-hydrochlorothiazide on lung function in infants with chronic bronchopulmonary dysplasia. <i>J Pediatr</i>. 1989;114(4 Pt 1):619-624.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/2926575/pubmed" id="2926575" target="_blank">2926575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fanaroff.2013">
<a name="Fanaroff.2013"></a>Fanaroff AA, Fanaroff JM, eds. <i>Klaus &amp; Fanaroff's Care of the High-Risk Neonate</i>. 6th ed. Philadelphia, PA: Elsevier Saunders; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-682358">
<a name="682358"></a>Feinfeld DA, Carvounis CP. Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment. <i>JAMA</i>. 1978;240(14):1516. doi:10.1001/jama.240.14.1516<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/682358/pubmed" id="682358" target="_blank">682358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35536535">
<a name="35536535"></a>Forestiero V, Sconfienza E, Mulatero P, Monticone S. Primary aldosteronism in pregnancy. <i>Rev Endocr Metab Disord</i>. Published online May 10, 2022. doi:10.1007/s11154-022-09729-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/35536535/pubmed" id="35536535" target="_blank">35536535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi:10.1210/jc.2015-4061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-426401">
<a name="426401"></a>Gabow PA, Moore S, Schrier RW. Spironolactone-induced hyperchloremic acidosis in cirrhosis. <i>Ann Intern Med</i>. 1979;90(3):338-340. doi:10.7326/0003-4819-90-3-338<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/426401/pubmed" id="426401" target="_blank">426401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27797886">
<a name="27797886"></a>Georgianos PI, Agarwal R. Pharmacotherapy of hypertension in chronic dialysis patients. <i>Clin J Am Soc Nephrol</i>. 2016;11(11):2062-2075. doi:10.2215/CJN.00870116<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/27797886/pubmed" id="27797886" target="_blank">27797886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21464748">
<a name="21464748"></a>Giefer MJ, Murray KF, Colletti RB. Pathophysiology, diagnosis, and management of pediatric ascites. <i>J Pediatr Gastroenterol Nutr</i>. 2011;52(5):503-513.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/21464748/pubmed" id="21464748" target="_blank">21464748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243703">
<a name="24243703"></a>Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/24243703/pubmed" id="24243703" target="_blank">24243703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6235834">
<a name="6235834"></a>Goodfellow A, Alaghband-Zadeh J, Carter G, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. <i>Br J Dermatol</i>. 1984;111(2):209-214. doi:10.1111/j.1365-2133.1984.tb04045.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/6235834/pubmed" id="6235834" target="_blank">6235834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Graber.2018">
<a name="Graber.2018"></a>Graber E. Acne vulgaris: Management of moderate to severe acne in adolescents and adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31419271">
<a name="31419271"></a>Gueiros APS, Gueiros JEB, Nóbrega KT, et al. Effect of spironolactone on the progression of coronary calcification in peritoneal dialysis patients: a pilot study. <i>J Bras Nefrol</i>. 2019;41(3):345-355. doi:10.1590/2175-8239-jbn-2019-0009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/31419271/pubmed" id="31419271" target="_blank">31419271</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30712923">
<a name="30712923"></a>Hammer F, Malzahn U, Donhauser J, et al.; MiREnDa Study Group. A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients.<i> Kidney Int.</i> 2019;95(4):983-991. doi:10.1016/j.kint.2018.11.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/30712923/pubmed" id="30712923" target="_blank">30712923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19648382">
<a name="19648382"></a>Haynes BA, Mookadam F. Male gynecomastia. <i>Mayo Clin Proc</i>. 2009;84(8):672. doi:10.1016/S0025-6196(11)60515-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/19648382/pubmed" id="19648382" target="_blank">19648382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29320642">
<a name="29320642"></a>Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. <i>Endocr Pract</i>. 2017;23(12):1437. doi:10.4158/1934-2403-23.12.1437<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/29320642/pubmed" id="29320642" target="_blank">29320642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10693099">
<a name="10693099"></a>Hoffman DJ, Gerdes JS, Abbasi S. Pulmonary function and electrolyte balance following spironolactone treatment in preterm infants with chronic lung disease: a double-blind, placebo-controlled, randomized trial. <i>J Perinatol</i>. 2000;20(1):41-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/10693099/pubmed" id="10693099" target="_blank">10693099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16779276">
<a name="16779276"></a>Huang C, Noirot LA, Reichley RM, Bouselli DA, Dunagan WC, Bailey TC. Automatic detection of spironolactone - related adverse drug events. <i>AMIA Annu Symp Proc</i>. 2005;2005:989.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/16779276/pubmed" id="16779276" target="_blank">16779276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24335969">
<a name="24335969"></a>Ito Y, Mizuno M, Suzuki Y, et al.; Nagoya Spiro Study Group. Long-term effects of spironolactone in peritoneal dialysis patients. <i>J Am Soc Nephrol</i>. 2014;25(5):1094-1102. doi:10.1681/ASN.2013030273<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/24335969/pubmed" id="24335969" target="_blank">24335969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34352345">
<a name="34352345"></a>James JF, Jamerson TA, Aguh C. Efficacy and safety profile of oral spironolactone use for androgenic alopecia: a systematic review. <i>J Am Acad Dermatol</i>. 2022;86(2):425-429. doi:10.1016/j.jaad.2021.07.048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/34352345/pubmed" id="34352345" target="_blank">34352345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3661395">
<a name="3661395"></a>Jeunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. <i>Am J Cardiol</i>. 1987;60(10):820-825. doi:10.1016/0002-9149(87)91030-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/3661395/pubmed" id="3661395" target="_blank">3661395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15295047">
<a name="15295047"></a>Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. <i>N Engl J Med</i>. 2004;351(6):543-551. doi:10.1056/NEJMoa040135<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/15295047/pubmed" id="15295047" target="_blank">15295047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30799782">
<a name="30799782"></a>Kallistratos MS, Pittaras A, Theodoulidis I, Grassos C, Poulimenos LE, Manolis AJ. Adverse effects of mineralocorticoid receptor antagonist administration. <i>Curr Pharm Des</i>. 2018;24(46):5537-5541. doi:10.2174/1381612825666190222144359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/30799782/pubmed" id="30799782" target="_blank">30799782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.2016">
<a name="Kliegman.2016"></a>Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5467162">
<a name="5467162"></a>Levitt JI. Spironolactone therapy and amenorrhea. <i>JAMA</i>. 1970;211(12):2014-2015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/5467162/pubmed" id="5467162" target="_blank">5467162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30352280">
<a name="30352280"></a>Liszewski W, Boull C. Lack of evidence for feminization of males exposed to spironolactone in utero: a systematic review. <i>J Am Acad Dermatol</i>. 2019;80(4):1147-1148.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/30352280/pubmed" id="30352280" target="_blank">30352280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27735065">
<a name="27735065"></a>Mackenzie IS, Morant SV, Wei L, Thompson AM, MacDonald TM. Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. <i>Br J Clin Pharmacol</i>. 2017;83(3):653-663. doi:10.1111/bcp.13152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/27735065/pubmed" id="27735065" target="_blank">27735065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33446410">
<a name="33446410"></a>Maddox TM, Januzzi JL Jr, Allen LA, et al. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. <i>J Am Coll Cardiol</i>. 2021;77(6):772-810. doi:10.1016/j.jacc.2020.11.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/33446410/pubmed" id="33446410" target="_blank">33446410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.1">
<a name="Mann.1"></a>Mann JFE, Flack JM. Choice of drug therapy in primary (essential) hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29522147">
<a name="29522147"></a>Martin KA, Anderson RR, Chang RJ, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2018;103(4):1233-1257. doi:10.1210/jc.2018-00241<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/29522147/pubmed" id="29522147" target="_blank">29522147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-McMichael.1">
<a name="McMichael.1"></a>McMichael A. Female pattern hair loss (androgenetic alopecia in females): management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 6, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26064481">
<a name="26064481"></a>Moustakakis MN, Bockorny M. Gitelman syndrome and pregnancy. <i>Clin Kidney J</i>. 2012;5(6):552-555. doi:10.1093/ckj/sfs126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/26064481/pubmed" id="26064481" target="_blank">26064481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2943311">
<a name="2943311"></a>Muhlemann MF, Carter GD, Cream JJ, Wise P. Oral spironolactone: an effective treatment for acne vulgaris in women. <i>Br J Dermatol</i>. 1986;115(2):227-232. doi:10.1111/j.1365-2133.1986.tb05722.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/2943311/pubmed" id="2943311" target="_blank">2943311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12468576">
<a name="12468576"></a>Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. <i>Hypertension</i>. 2002;40(6):897-902.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/12468576/pubmed" id="12468576" target="_blank">12468576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286277">
<a name="15286277"></a>National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. <i>Pediatrics</i>. 2004;114(2)(suppl 4th Report):555-576.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/15286277/pubmed" id="15286277" target="_blank">15286277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25827472">
<a name="25827472"></a>Nuttall FQ, Warrier RS, Gannon MC. Gynecomastia and drugs: a critical evaluation of the literature. <i>Eur J Clin Pharmacol</i>. 2015;71(5):569-578. doi:10.1007/s00228-015-1835-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/25827472/pubmed" id="25827472" target="_blank">25827472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(4):e362-e425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24107738">
<a name="24107738"></a>Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. <i>J Hypertens</i>. 2013;31(10):2094-2102. doi:10.1097/HJH.0b013e3283638b1a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/24107738/pubmed" id="24107738" target="_blank">24107738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.2014">
<a name="Park.2014"></a>Park, MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 6th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-894512">
<a name="894512"></a>Phelps DL, Karim A. Spironolactone: relationship between concentrations of dethioacetylated metabolite in human serum and milk. <i>J Pharm Sci</i>. 1977;66(8):1203.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/894512/pubmed" id="894512" target="_blank">894512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24716680">
<a name="24716680"></a>Pitt B, Pfeffer MA, Assmann SF, et al; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. <i>N Engl J Med</i>. 2014;370(15):1383-1392. doi:10.1056/NEJMoa1313731<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/24716680/pubmed" id="24716680" target="_blank">24716680</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12668699">
<a name="12668699"></a>Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [published correction appears in N Engl J Med. 2003 May 29;348(22):2271]. <i>N Engl J Med</i>. 2003;348(14):1309-1321. doi:10.1056/NEJMoa030207<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/12668699/pubmed" id="12668699" target="_blank">12668699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10471456">
<a name="10471456"></a>Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. <i>N Engl J Med</i>. 1999;341(10):709-717. doi:10.1056/NEJM199909023411001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/10471456/pubmed" id="10471456" target="_blank">10471456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2540730">
<a name="2540730"></a>Prior JC, Vigna YM, Watson D. Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism. <i>Arch Sex Behav</i>. 1989;18(1):49-57. doi:10.1007/bf01579291<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/2540730/pubmed" id="2540730" target="_blank">2540730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15860966">
<a name="15860966"></a>Prisant LM, Chin E. Gynecomastia and hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2005;7(4):245-248. doi:10.1111/j.1524-6175.2005.04105.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/15860966/pubmed" id="15860966" target="_blank">15860966</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25163723">
<a name="25163723"></a>Riester A, Reincke M. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy. <i>Eur J Endocrinol</i>. 2015;172(1):R23-R30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/25163723/pubmed" id="25163723" target="_blank">25163723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-907238">
<a name="907238"></a>Rose LI, Underwood RH, Newmark SR, Kisch ES, Williams GH. Pathophysiology of spironolactone-induced gynecomastia. <i>Ann Intern Med</i>. 1977;87(4):398-403. doi:10.7326/0003-4819-87-4-398<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/907238/pubmed" id="907238" target="_blank">907238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30467659">
<a name="30467659"></a>Rozner RN, Freites-Martinez A, Shapiro J, Geer EB, Goldfarb S, Lacouture ME. Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. <i>Breast Cancer Res Treat</i>. 2019;174(1):15-26. doi:10.1007/s10549-018-4996-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/30467659/pubmed" id="30467659" target="_blank">30467659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Runyon.2020">
<a name="Runyon.2020"></a>Runyon BA. Ascites in adults with cirrhosis: Initial therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23463403">
<a name="23463403"></a>Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases practice guideline management of adult patients with ascites due to cirrhosis 2012. <i>Hepatology</i>. 2013;57(4):1651-1653. doi:10.1002/hep.26359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/23463403/pubmed" id="23463403" target="_blank">23463403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31418056">
<a name="31418056"></a>Sabatier P, Amar J, Montastruc F, et al. Breast cancer and spironolactone: an observational postmarketing study. <i>Eur J Clin Pharmacol</i>. 2019;75(11):1593-1598. doi:10.1007/s00228-019-02740-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/31418056/pubmed" id="31418056" target="_blank">31418056</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12734047">
<a name="12734047"></a>Sabri M, Saps M, Peters JM. Pathophysiology and management of pediatric ascites. <i>Curr Gastroenterol Rep</i>. 2003;5(3):240-246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/12734047/pubmed" id="12734047" target="_blank">12734047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35686552">
<a name="35686552"></a>Sanga V, Rossitto G, Seccia TM, Rossi GP. Management and outcomes of primary aldosteronism in pregnancy: a systematic review. <i>Hypertension</i>. 2022;79(9):1912-1921. doi:10.1161/HYPERTENSIONAHA.121.18858<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/35686552/pubmed" id="35686552" target="_blank">35686552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16139135">
<a name="16139135"></a>Shah KB, Rao K, Sawyer R, Gottlieb SS. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. <i>J Am Coll Cardiol</i>. 2005;46(5):845-849. doi:10.1016/j.jacc.2005.06.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/16139135/pubmed" id="16139135" target="_blank">16139135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30867665">
<a name="30867665"></a>Shahzad MA, Mukhtar M, Ahmed A, Ullah W, Saeed R, Hamid M. Gitelman syndrome: a rare cause of seizure disorder and a systematic review. <i>Case Rep Med</i>. 2019;2019:4204907. doi:10.1155/2019/4204907<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/30867665/pubmed" id="30867665" target="_blank">30867665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10954662">
<a name="10954662"></a>Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. <i>J Am Acad Dermatol</i>. 2000;43(3):498-502. doi:10.1067/mjd.2000.105557<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/10954662/pubmed" id="10954662" target="_blank">10954662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15787815">
<a name="15787815"></a>Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. <i>Br J Dermatol</i>. 2005;152(3):466-473. doi:10.1111/j.1365-2133.2005.06218.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/15787815/pubmed" id="15787815" target="_blank">15787815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23478874">
<a name="23478874"></a>Slaughter JL, Stenger MR, Reagan PB. Variation in the use of diuretic therapy for infants with bronchopulmonary dysplasia. <i>Pediatrics</i>. 2013;131(4):716-723.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/23478874/pubmed" id="23478874" target="_blank">23478874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22052934">
<a name="22052934"></a>Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACC Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation. <i>Circulation</i>. 2011;124(22):2458-2473.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/22052934/pubmed" id="22052934" target="_blank">22052934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31110051">
<a name="31110051"></a>Spinowitz BS, Fishbane S, Pergola PE, et al.; ZS-005 Study Investigators. Sodium zirconium cyclosilicate among Individuals with hyperkalemia: a 12-month phase 3 study. <i>Clin J Am Soc Nephrol</i>. 2019;14(6):798-809. doi:10.2215/CJN.12651018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/31110051/pubmed" id="31110051" target="_blank">31110051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21901679">
<a name="21901679"></a>Stewart A, Brion LP, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. <i>Cochrane Database Syst Rev</i>. 2011;(9):CD001817.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/21901679/pubmed" id="21901679" target="_blank">21901679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15632880">
<a name="15632880"></a>Tamirisa KP, Aaronson KD, Koelling TM. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. <i>Am Heart J</i>. 2004;148(6):971-978. doi:10.1016/j.ahj.2004.10.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/15632880/pubmed" id="15632880" target="_blank">15632880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31360748">
<a name="31360748"></a>Thiede RM, Rastogi S, Nardone B, et al. Hyperkalemia in women with acne exposed to oral spironolactone: a retrospective study from the RADAR (Research on Adverse Drug Events and Reports) program. <i>Int J Womens Dermatol</i>. 2019;5(3):155-157. doi:10.1016/j.ijwd.2019.04.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/31360748/pubmed" id="31360748" target="_blank">31360748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2016">
<a name="CDC.2016"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11607853">
<a name="11607853"></a>Vachharajani AJ, Shah JK, Paes BA. Ovarian cyst in a premature infant treated with spironolactone. <i>Am J Perinatol</i>. 2001;18(6):353-356.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/11607853/pubmed" id="11607853" target="_blank">11607853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16898855">
<a name="16898855"></a>van der Vorst MM, Kist JE, van der Heijden AJ, Burggraaf J. Diuretics in pediatrics: current knowledge and future prospects. <i>Paediatr Drugs</i>. 2006;8(4):245-264.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/16898855/pubmed" id="16898855" target="_blank">16898855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24812304">
<a name="24812304"></a>Vardeny O, Claggett B, Anand I, et al. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. <i>Circ Heart Fail</i>. 2014;7(4):573-579. doi:10.1161/CIRCHEARTFAILURE.114.001104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/24812304/pubmed" id="24812304" target="_blank">24812304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26. doi:10.1111/jch.12237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in <i>Hypertension</i>. 2018;71(6):e140-e144]. <i>Hypertension</i>. 2018;71(6):e13-e115. doi:10.1161/HYP.0000000000000065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9161653">
<a name="9161653"></a>Whitling AM, Pérgola PE, Sang JL, Talbert RL. Spironolactone-induced agranulocytosis. <i>Ann Pharmacother</i>. 1997;31(5):582-585. doi:10.1177/106002809703100511<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/9161653/pubmed" id="9161653" target="_blank">9161653</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26414968">
<a name="26414968"></a>Williams B, MacDonald TM, Morant S, et al; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. <i>Lancet</i>. 2015;386(10008):2059-2068. doi:10.1016/S0140-6736(15)00257-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/26414968/pubmed" id="26414968" target="_blank">26414968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2002">
<a name="WHO.2002"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23741058">
<a name="23741058"></a>Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;128(16):e240-e327. doi:10.1161/CIR.0b013e31829e8776<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/23741058/pubmed" id="23741058" target="_blank">23741058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15752283">
<a name="15752283"></a>Yemisci A, Gorgulu A, Piskin S. Effects and side-effects of spironolactone therapy in women with acne. <i>J Eur Acad Dermatol Venereol</i>. 2005;19(2):163-166. doi:10.1111/j.1468-3083.2005.01072.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/15752283/pubmed" id="15752283" target="_blank">15752283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Young.2019">
<a name="Young.2019"></a>Young WF Jr. Treatment of primary aldosteronism. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 10, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26897386">
<a name="26897386"></a>Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. <i>J Am Acad Dermatol. </i>2016;74(5):945-973.e33. doi:10.1016/j.jaad.2015.12.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/spironolactone-pediatric-drug-information/abstract-text/26897386/pubmed" id="26897386" target="_blank">26897386</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12803 Version 511.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
